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Introduction: Sepsis is a leading global cause of
morbidity and mortality, and is more common at the
extremes of age. Moreover, the cost of in-hospital care
for elderly patients with sepsis is significant. There are
indications from experimental and observational
studies that aspirin may reduce inflammation
associated with infection. This paper describes the
rationale and design of the AspiriN To Inhibit SEPSIS
(ANTISEPSIS) trial, a substudy of ASPirin in Reducing
Events in the Elderly (ASPREE). ANTISEPSIS primarily
aims to determine whether low-dose aspirin reduces
sepsis-related deaths in older people. Additionally, it
will assess whether low-dose aspirin reduces sepsis-
related hospitalisations and sepsis-related Intensive
Care Unit (ICU) admissions.
Methods and analysis: ASPREE is a double-blinded,
randomised, placebo-controlled primary prevention trial
that will determine whether daily low-dose aspirin
extends disability-free longevity in 19 000 healthy older
people recruited in Australia and the USA. The
ANTISEPSIS substudy involves additional ASPREE trial
data collection to assess the impact of daily low-dose
aspirin on sepsis-related events in the 16 703 ASPREE
participants aged 70 years and over, recruited in
Australia. The intervention is a daily 100 mg dose of
enteric-coated aspirin versus matching placebo, with
1:1 randomisation. The primary outcome for the
ANTISEPSIS substudy is the incidence of sepsis-
related death in eligible patients. The incidence of
sepsis-related hospital and ICU admissions are
secondary outcomes. ANTISEPSIS is to be conducted
between 2012 and 2018.
Discussion: This substudy will determine whether
aspirin, an inexpensive and accessible therapy, safely
reduces sepsis-related deaths and hospitalisations in
older Australians. If shown to be the case, this would
have profound effects on the health of older
Australians.
Trial registration number: Pre-results,
ACTRN12613000349741.
INTRODUCTION
Joseph Lister pioneered a crucial aspect of
modern health practice when he first used
carbolic acid solution to prevent severe infec-
tion in a contaminated wound. Antisepsis is
used in all aspects of healthcare and daily
life to protect us from pathogenic microor-
ganisms. With the AspiriN To Inhibit SEPSIS
(ANTISEPSIS) trial, we aim to confirm
whether a simple and cheap health interven-
tion can protect against manifestations of
severe infection by modulating the human
host response to infection, regardless of the
specific causative microbe.
Sepsis is a lethal condition that kills one
person a minute globally. Lower respiratory
tract infections alone caused 5.5% of all
deaths in 2012, making them the third most
common cause of death.1 More specifically,
in relation to our study, lower respiratory
tract infections are the cause of an extremely
high number of sepsis deaths in the elderly
in the developed world.2
Septic shock has hospital mortality in
excess of 40%.3 Incremental reduction in
sepsis mortality has been achieved in high-
income countries through early recognition
and optimisation of immediate treatment
delivered in well-resourced hospitals.4
However, this reduction mainly parallels
general improvements in mortality of
patients admitted to the ICU.
Sepsis therapy research is bedevilled with
failed attempts at proving efficacy of specific
treatments.5 Adjuvant treatments for sepsis
Strengths and limitations of this study
▪ This trial uses the unequivocal measure of death
due to sepsis as its primary end point.
▪ This large-scale primary prevention trial will be
adequately powered to test the study hypothesis.
▪ There is, however, no opportunity to examine the
biological basis for any demonstrated effect, as
real-time samples are not available at the time of
sepsis episodes.
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that have been developed and trialled at major cost have
failed to deliver significant reduction in mortality. There
is no effective sepsis prevention strategy aimed at modu-
lating the deleterious host inflammatory response to
severe infection.
Aspirin is one of the most widely used drugs in the
world today, shaping the face of modern health with its
potent preventive activity against atherothrombotic vas-
cular disease.6 Low doses of aspirin of <150 mg/day are
sufficient for the antiplatelet effect required for stroke
and cardioprotection. These low doses of aspirin are
now also being recognised as mediating anti-
inflammatory effects, and therefore may be effective in
preventing severe manifestations of sepsis.7
The cause of death in elderly patients with sepsis is
usually multifactorial. Crucially though, sepsis constitutes
a triggering and contributory factor for mortality. In this
regard, considering multiple causes of death gives a
more appropriate assessment of contributing factors to
death in the elderly rather than the assessment of a
single cause of death. Adding a simple preventive
therapy with overlapping effects in reduction of cardio-
vascular and sepsis risks would be of major benefit to
the health of Australia’s ageing population by reducing
health costs. Aspirin has the potential to fulfil that role.
Examination of the biological bases of aspirin in limit-
ing the deleterious effects of the septic inflammatory
cascade is illuminating. Aspirin has effects on at least
three sepsis/inflammation pathways.
Tumour necrosis factor (TNF) and interleukin-6 are
canonical proinflammatory cytokines. In sepsis, immune
cell receptors recognise pathogen associated molecular
patterns mediating intracellular signalling events that
result in nuclear factor kappa-beta (NFκB) activation.
This then results in transcription of TNF. NFκB activa-
tion is inhibited by aspirin and other non-steroidal anti-
inflammatory drugs (NSAIDs). This is mediated by
inhibition of Ikk-B.8 The concentration of NSAIDs
required for this inhibition has been measured to be
lower than aspirin.9 The low range of aspirin for this
effect has not been defined.
Lipid mediators of sepsis have recently been
described.10 A number of these molecules act as anti-
inflammatories and also to restore homeostasis.11 12 In
sepsis, they reduce established inflammation by mechan-
isms including restoration of polymorphonuclear apop-
tosis which limits continued production of
proinflammatory cytokines in tissues and increase of
nitric oxide synthesis.13 Low doses of aspirin have been
shown to increase lipoxins (aspirin triggered lipoxin
(ATL)) and resolvins in vitro11 12 and in human trials.14
Furthermore, ATL mediated, salutary effects have been
shown in animal and human disease models of sepsis
and inflammation. Animal models demonstrate that
aspirin given both before and after onset of sepsis
reduces mortality.15 Low-dose aspirin increases nitric
oxide production as seen in experimental animals.16
Additionally, in a human model, ATL accounts for
prevention of skin blister via reduced neutrophil and
macrophage accumulation.17 Crucially, these beneficial
effects are unique to aspirin among the NSAIDs as it
alone increases ATL.
Platelets become activated in sepsis due to interaction
with invading bacteria via three broad mechanisms.
These constitute: (1) binding of bacteria to plasma pro-
teins which are ligands for platelet receptors, (2) direct
bacterial binding to platelet receptors and (3) secretion
of aspirin binding bacterial products such as toxins.18
Aspirin reduces activation of platelets by inhibition of
cyclooxygenase I.19
Bleeding risks in patients taking regular aspirin are
clearly defined. Among primary prevention trial partici-
pants taking between 700 and 1625 mg aspirin per week,
the increased risk of all gastrointestinal haemorrhage
was 1.27 (95% CI 1.05 to 1.55).20 21 This must be
balanced against potential benefits of low-dose aspirin
therapy, including for sepsis prevention.
Numerous observational studies have investigated the
influence of long-term aspirin use prior to onset of
sepsis.22–34 A number of these propensity-matched
studies show that long-term aspirin use is associated with
reduced mortality.22–28 30–32
These observational data, along with the effect of
low-dose aspirin on inflammatory pathways, provide a
compelling background for investigation of possible
reduction in sepsis deaths in ANTISEPSIS. Therefore,
this doubled blind, placebo controlled, randomised con-
trolled primary prevention trial (RCT) will investigate
whether low-dose aspirin reduces deaths due to sepsis.
STUDY METHODS
ANTISEPSIS is a substudy of the ASPirin in Reducing
Events in the Elderly study (ASPREE). ASPREE is an
Australian/US randomised, double blind, placebo con-
trolled, primary prevention trial of low-dose aspirin in
the elderly. ASPREE will measure the effect of low-dose
aspirin on numerous outcomes: all-cause mortality, inci-
dent dementia, persistent physical disability, cardiovascu-
lar and major haemorrhagic events, and cancer
incidence. ANTISEPSIS is embedded in the study design
of the ASPREE principal study. Monitoring and event
reporting for ANTISEPSIS is conducted with NHMRC
funding of staff within the ASPREE data and document
collection team. ANTISEPSIS is being conducted
between 2012 and 2018.
Hypothesis and aims
We hypothesise that severe outcomes relating to sepsis in
the elderly may be prevented by daily low-dose aspirin.
We will conduct the ANTISEPSIS trial using the infra-
structure of the ASPREE RCT. We will extend sepsis
event data collection in ASPREE participants to assess
our primary end point:
▸ Reduction of deaths contributed to by sepsis in parti-
cipants receiving aspirin versus placebo.
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We will also conduct an analysis of two secondary end
points:
▸ Reduction of sepsis episodes requiring hospital
admissions
▸ Reduction of intensive care unit (ICU) admissions
among patients hospitalised for severe sepsis.
Antisepsis study design
Detailed methods for the ASPREE ‘principal’ study are
described in the ASPREE protocol available on the
aspree.org website—http://www.aspree.org/AUS/aspree-
content/aspree-study- details/aspree-materials.aspx/ and
in the ASPREE methods paper.35
Only the Australian ASPREE participants are included
in the ANTISEPSIS study. This stems from the adequacy
of the Australian ASPREE sample size for the
ANTISEPSIS end points. Furthermore, the absence of
detailed ICU data on participants from the USA means
that there would be insufficient data to adjudicate all
sepsis end points.
The design of the ANTISEPSIS trial mirrors that of the
principal ASPREE study. ANTISEPSIS is also a trial of
100 mg enteric-coated aspirin taken daily versus match-
ing placebo. ASPREE trial participants were recruited
through their primary care general practices. One to one
randomisation of Australian participants was stratified for
general practice and for age (70–79 or ≥80 years).
ANTISEPSIS recruits from ASPREE participants and
hence the exclusion/inclusion criteria for the ASPREE
study apply. The participants in the ASPREE principal
trial were required to be free of previous cardiovascular
disease or stroke, have preserved intellectual function
and have no known illness that would preclude their
follow-up participation within the next 3–5 years. Apart
from this, they are broadly representative of the healthy
elderly population.
The details on: study medication and supplies, screen-
ing visit and run-in placebo for the ASPREE trial, ran-
domisation visit, scheduled visits and measurements are
as per the ASPREE protocol.35
Antisepsis end point determination
Demographic data describing age, sex, body habitus,
comorbidities, smoking history, alcohol intake and con-
comitant medications at ASPREE entry are available
from the ASPREE study. Data related to the three end
points of the ANTISEPSIS trial are available from
general practitioner (GP) clinics, hospital documenta-
tion and death certificates. Additional demographic,
severity of illness and outcome data on patients admitted
to ICUs will be obtained by merging ASPREE data with
information from the Australian and New Zealand
Intensive Care Society (ANZICS) Adult Patient Database
(APD), one of four clinical quality registries run by the
ANZICS Centre for Outcome and Resource Evaluation
(CORE).
Since ASPREE data only provide International
Classification of Diseases 10th Revision hospital primary
admission codes, ANTISEPSIS will examine all hospital
discharge summaries and death certificates from
ASPREE participants identified as having a possible
sepsis end point to ensure complete capture of sepsis
episodes. The search for hospitalisation data relies on a
number of source materials. The ASPREE operational
process captures all hospitalisations, although some hos-
pital discharge summaries may be blank. In that
instance, GP records will be examined for information
regarding the reason for hospitalisation. ASPREE partici-
pants also report admission(s) on yearly review and
ASPREE operational processes also identify participant
deaths. Death Certificates are retrieved for ASPREE
patients who die outside of an acute hospital admission.
Missing data on hospitalisation admission/discharge
diagnoses are flagged for priority retrieval by ASPREE
monitors/study personnel at GP visits.
ANTISEPSIS study research staff extract information
relating to:
▸ Nature of sepsis episode, diagnosis, infecting organ-
ism (if available).
▸ Sepsis severity; ICU admission, disease severity at ICU
admission (Acute Physiology Chronic Health
Evaluation (APACHE) II score), prognostic score
(APACHE risk of death (APACHE II score with adjust-
ment for site of infection))
▸ Sepsis episode outcome; survival or death.
▸ Time of sepsis episode from ASPREE study medica-
tion initiation for survival analysis.
Data extracted from the ANZICS APD include:
▸ Sepsis severity and criteria, ICU length of stay, disease
severity at ICU admission (APACHE II and III
scores), predicted risk of death (derived from the
APACHE III scoring system and using the ‘ANZ Risk
of Death’ model), ICU and hospital outcomes.
An electronic case report form has been designed for
input of ANTISEPSIS Study end point data into the
ASPREE web-based data acquisition system.
Antisepsis case definitions
Sepsis definition
Sepsis is defined as the presence of the systemic inflam-
matory response syndrome (SIRS; the presence of two
or more of: temperature <36° C or >38° C, heart rate
>90 bpm, respiratory rate >20 breaths/min or PaCO2
<32 mm Hg, and white cell count >12 000 or <4000
cells/mm3 or >10% bands)36 plus documented infection
as described below. The use of SIRS criteria for defin-
ition of sepsis relates to the timing of ANTISEPSIS
protocol development and study initiation. ANTISEPSIS
started before the development of the Third
International Consensus Definitions for Sepsis and
Septic Shock (Sepsis-3).3
Infection site definitions
Primary blood stream infection is defined as recognised
pathogen (defined as a microorganism not usually
regarded as a common skin contaminant) cultured from
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one or more blood cultures, or a common skin contam-
inant cultured from two or more blood cultures drawn
on separate occasions and the organism cultured from
blood is not related to an infection at another site,
including intravascular-access devices.37
Pneumonia is defined as a chest radiograph within
24 hours of hospital admission demonstrating features
consistent with acute pneumonia; and at least two symp-
toms consistent with pneumonia (eg, fever or hypother-
mia, rigours, sweats, new cough (with or without
sputum), chest discomfort or new onset of dyspnoea).38
Hospital-acquired pneumonia is defined as pneumonia
that occurs 48 hours or more after admission, which was
not incubating at the time of admission.39
Meningitis is defined as increased white cells, elevated
protein and decreased glucose in cerebrospinal fluid
(CSF) (per reporting laboratory’s reference range), or
organisms seen on Gram stain of CSF, or organisms
identified from blood by a culture or non-culture-based
microbiological testing method which is performed for
purposes of clinical diagnosis or treatment.40
Urinary tract infection (UTI) is defined as at least one of:
fever >38°C, suprapubic tenderness, costovertebral angle
pain or tenderness, urinary frequency, urinary urgency or
dysuria and urine culture with no more than two species
of organisms, at least one of which is a bacterium of ≥105
colony forming units/mL.41 UTI is either non-catheter
associated or, where a urinary catheter has been in situ
for at least 2 days, catheter associated.
Skin and soft tissue infection:
A. Cellulitis is defined as any spreading infection involv-
ing the dermis and subcutaneous tissues.42
B. Abscess is defined as any collection of pus within the
dermis or subcutaneous tissues.42
C. Necrotising soft tissue infection is defined as a necrotis-
ing infection involving any of the soft tissue layers,
including the dermis, subcutaneous tissue, superficial
or deep fascia, and muscle.42
Peritonitis is defined as a clinically compatible illness with
abdominal pain and guarding associated with documen-
ted evidence of perforation (free air in the abdomen on
radiographic studies or surgical confirmation of periton-
eal inflammation following luminal perforation).37
Bone and joint infection is defined as the presence of
organisms grown from bone or joint tissues by microbio-
logical culture in a patient with bony pain, tenderness
or drainage.40
Infective endocarditis is diagnosed according to modified
Duke’s Criteria.43
Gastroenteritis is defined as the acute onset of diarrhoea
(liquid stools for >12 hours) and no likely non-infectious
cause with an enteric pathogen identified from stool or
rectal swab by a culture or non-culture-based microbio-
logical method.40
The approval by the Monash University Human
Research Ethics Committee for ANTISEPSIS includes
authorisation to contact local pathology services to
extract individual patient pathology results to confirm
the presence of sepsis.
End point definitions
The primary end point, death due to sepsis, is defined
as death of an ASPREE participant who had been either
admitted to hospital for an infection episode or where
such an episode of infection develops in hospital and in
either case, the infection episode contributes to death
(as determined by hospital records and/or a death cer-
tificate). If ASPREE participants die out of hospital, the
death certificate will be used to determine whether
sepsis was a contributory cause of death.
Secondary study end points are defined as (1) non-
fatal sepsis during hospital admission of an ASPREE par-
ticipant due to an infection episode defined as above,
(2) non-fatal sepsis/septic shock during ICU admission
of an ASPREE participant due to an infection episode
defined as above.
End point adjudication
An end point adjudication committee consisting of
ANTISEPSIS investigators who are Infectious Diseases
and ICU staff specialist physicians decides outcomes.
The adjudication process is web-based and all those
involved are blinded to group allocation. Two
ANTISEPSIS adjudicators review each event independ-
ently. Where there is agreement, this is the outcome of
the event. Discordant results go to a third reviewer for
the final adjudication.
Trial safe conduct—data safety monitoring board
The safety routine for ANTISEPSIS is as established for
ASPREE. All serious adverse events and adverse events
are registered with the ASPREE trial according to the
established protocol and then presented to an inde-
pendent Data Safety and Monitoring Board (DSMB;
established by the National Institute on Ageing) and to
Human Research Ethics Committees. The DSMB over-
sees the ASPREE study to monitor quality control of the
data, progress of recruitment and safety aspects of the
ASPREE trial.
Sample size and study power
At the time that ANTISEPSIS was designed, available
observational data showed a relative effect size on sepsis
mortality in patients in ICU taking long-term aspirin
prior to ICU admission, in the order of 40–80%.22 25
These data are from two studies with a fundamentally
different design. One was an observational study of
Australian patients in ICU, which showed that patients
taking aspirin prior to hospitalisation with SIRS who
were continued on aspirin had an OR of 0.6 for
in-hospital mortality compared with those not treated
with aspirin. The HR calculated from this study for mor-
tality in patients with SIRS treated with aspirin was 0.63.
The group of patients with proven sepsis had an OR of
0.52 for mortality.22 The other single centre German
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study of aspirin in ICU patients showed reduced mortal-
ity (OR 0.19) in patients with an unrestricted range of
admission diagnoses.25
Using an HR of 0.63 to examine the sample size
required to power our ANTISEPSIS study for the
outcome of sepsis-related mortality is a conservative
approach given the lower ORs available from the
German study and Australian patients with proven
sepsis. However, we reasoned that the SIRS OR was the
most reliable representation of the likely magnitude of
aspirin effects on the inflammatory pathways common
to SIRS and sepsis given that this figure is based on a
large cohort (n=5525) of first SIRS episodes.
The ASPREE study rate of death was estimated to be
17.6 per 1000 participant years. Approximately
4.75 years average follow-up time per participant will be
available in an analysis of time to death. We assumed
that 20% of the deaths in ASPREE participants would be
contributed to by sepsis (as supported by Australian
data30). This provides an event rate for the primary end
point of ANTISEPSIS of 3.5 per 1000 participant years.
Anticipating half of 16 000 Australian ASPREE partici-
pants to be randomised to placebo and an event rate of
3.5 per 1000 participant year, we expect 133 primary
end point events in the placebo group. With this
number of sepsis-related deaths, we would have 80%
power to detect an HR of 0.69 for aspirin versus placebo
groups. If only 15% of ASPREE deaths are contributed
to by sepsis, we would instead expect 100 primary end
point events in the control group and still have 80%
power to detect an HR of 0.65. In either of these scen-
arios, the ANTISEPSIS study is powered to detect an
effect less than the HR of 0.63 measured previously.26
The two secondary end points, admission to hospital for
sepsis and admission to ICU for sepsis, are more
common than death due to sepsis,3 4 so they will be
powered to detect smaller effects than outlined above
for the primary end point.
Data analysis
We will analyse our primary and two secondary end
points without Bonferroni correction using univariate
survival analysis methods: the log-rank test and Cox pro-
portional hazards regression. The proportional hazards
assumption will be tested as part of the analysis. In sub-
sequent analysis, we will adjust for the following variables
known to influence mortality due to sepsis: diabetes, age
at recruitment, malignancy, alcohol intake and smoking
or chronic lung disease.
The main analyses will compare participant groups as
randomised, that is, intention to treat. A per protocol
analysis will also be performed.
ANTISEPSIS trial results will be reported according to
the CONSORT statement.44
Ethical conduct of the trial
This study will be conducted in accordance with the
ICH GCP Note for Guidance on Good Clinical Practice
(CPMP/ICH/135/95) annotated with TGA comments
and NH&MRC National Statement on Ethical Conduct
in Human Research 2007 protocols, and in keeping with
local regulations.
Informed consent
The need for individual informed consent for inclusion
of ASPREE participants in ANTISEPSIS has been waived
by the Monash University Human Research Ethics
Committee in its approval of the ANTISEPSIS study. The
ANTISEPSIS study conforms to the conditions set out in
CHAPTER 2.3: QUALIFYING OR WAIVING
CONDITIONS FOR CONSENT in the National
Statement on Ethical Conduct in Human Research 2007.
Trial registration
ANTISEPSIS is registered with the Australian New
Zealand Clinical Trials Registry ACTRN12613000349741.
The ASPREE study is registered with the International
Standard Randomised Controlled Trials Register,
ASPirin in Reducing Events in the Elderly,
ISRCTN83772183 and clinicaltrials.gov NCT01038583.
DISCUSSION
Primary prevention with aspirin appears to reduce all-
cause mortality. A meta-analysis of 100 000 aspirin
primary prevention trial patient outcomes showed that
this reduced all-cause mortality (OR, 0.94; 95% CI 0.88
to 1.00) and that this reduction was due neither to
reduced cardiovascular nor cancer deaths.21 However,
deaths due to cancer do appear to be reduced in a
meta-analysis of long-term follow-up of 25 570 partici-
pants from primary and secondary prevention aspirin
trials. Here, the reduction of cancer deaths with aspirin
therapy increased with duration of treatment.45 This
finding can therefore be viewed as being separate from
the non-cancer reduction of all-cause mortality from
primary prevention studies. No analysis of non-
cardiovascular or non-cancer mortality has been under-
taken on data from primary or secondary aspirin preven-
tion studies. It may be that one of the previously
unmeasured pathways by which aspirin reduces all-cause
mortality is via a reduction in sepsis deaths when aspirin
is used for primary prevention. We will test this hypoth-
esis in the ANTISEPSIS trial.
Recruitment to ASPREE was completed in December
2014 with a final number of 16 703 participants in
Australia. The collection of information on end points
will conclude at the end of 2017 and the unblinding of
the principal ASPREE trial, and therefore ANTISEPSIS,
is expected in mid-2018. If aspirin is shown to be effect-
ive in reducing the impact of severe sepsis, it will be the
first time that such an outcome has been demonstrated.
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